Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Damrongwatanasuk, Rongras; Fradley, Michael G

Damrongwatanasuk, Rongras; Fradley, Michael G.

Afiliação

Damrongwatanasuk R; Cardio-Oncology Program, Division of Cardiovascular Medicine, University of South Florida and H. Lee Moffitt Cancer Center & Research Institute, 2 Tampa General Circle, Tampa, FL, 33606, USA.
Fradley MG; Cardio-Oncology Program, Division of Cardiovascular Medicine, University of South Florida and H. Lee Moffitt Cancer Center & Research Institute, 2 Tampa General Circle, Tampa, FL, 33606, USA. mfradley@health.usf.edu.

Curr Treat Options Cardiovasc Med ; 19(4): 24, 2017 Apr.

Article em En | MEDLINE | ID: mdl-28316033

Palavras-chave

Cardio-oncology; Cardiotoxicity; Chronic myeloid leukemia; Nilotinib; Ponatinib; Tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Treat Options Cardiovasc Med Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google